Efficacy & Safety of TD-1473 in Ulcerative Colitis
Public ClinicalTrials.gov record NCT03758443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
Study identification
- NCT ID
- NCT03758443
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 239 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2019 (Actual)
- Primary completion
- Oct 20, 2021 (Actual)
- Completion
- Oct 20, 2021 (Actual)
- Last update posted
- Nov 15, 2022
2019 – 2021
United States locations
- U.S. sites
- 38
- U.S. states
- 19
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Theravance Biopharma Investigational Site | Chula Vista | California | 91911 | — |
| Theravance Biopharma Investigational Site | La Jolla | California | 92037 | — |
| Theravance Biopharma Investigational Site | Lancaster | California | 93534 | — |
| Theravance Biopharma Investigational Site | Orange | California | 92866 | — |
| Theravance Biopharma Investigational Site | Colorado Springs | Colorado | 80920 | — |
| Theravance Biopharma Investigational Site | Aventura | Florida | 33180 | — |
| Theravance Biopharma Investigational Site | Clearwater | Florida | 33756 | — |
| Theravance Biopharma Investigational Site | Largo | Florida | 33777 | — |
| Theravance Biopharma Investigational Site | Miami | Florida | 33135 | — |
| Theravance Biopharma Investigational Site | Miami | Florida | 33155 | — |
| Theravance Biopharma Investigational Site | New Port Richey | Florida | 34653 | — |
| Theravance Biopharma Investigational Site | New Smyrna Beach | Florida | 32168 | — |
| Theravance Biopharma Investigational Site | Orlando | Florida | 32803 | — |
| Theravance Biopharma Investigational Site | Pembroke Pines | Florida | 33024 | — |
| Theravance Biopharma Investigational Site | Atlanta | Georgia | 30342 | — |
| Theravance Biopharma Investigational Site | Suwanee | Georgia | 30024 | — |
| Theravance Biopharma Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Theravance Biopharma Investigational Site | Kansas City | Kansas | 66160 | — |
| Theravance Biopharma Investigational Site | Louisville | Kentucky | 40202 | — |
| Theravance Biopharma Investigational Site | Monroe | Louisiana | 71201 | — |
| Theravance Biopharma Investigational Site | Baltimore | Maryland | 21201 | — |
| Theravance Biopharma Investigational Site | Troy | Michigan | 48098 | — |
| Theravance Biopharma Investigational Site | Wyoming | Michigan | 48519 | — |
| Theravance Biopharma Investigational Site | Rochester | Minnesota | 55905 | — |
| Theravance Biopharma Investigational Site | Kansas City | Missouri | 64131 | — |
| Theravance Biopharma Investigational Site | Las Vegas | Nevada | 89123 | — |
| Theravance Biopharma Investigational Site | New York | New York | 10029 | — |
| Theravance Biopharma Investigational Site | Charlotte | North Carolina | 28215 | — |
| Theravance Biopharma Investigational Site | Gastonia | North Carolina | 28054 | — |
| Theravance Biopharma Investigational Site | Greenville | North Carolina | 27834-3761 | — |
| Theravance Biopharma Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| Theravance Biopharma Investigational Site | Smithfield | Pennsylvania | 15478 | — |
| Theravance Biopharma Investigational Site | Greenville | South Carolina | 29615 | — |
| Theravance Biopharma Investigational Site | Rock Hill | South Carolina | 29732 | — |
| Theravance Biopharma Investigational Site | Nashville | Tennessee | 37212 | — |
| Theravance Biopharma Investigational Site | Garland | Texas | 75044 | — |
| Theravance Biopharma Investigational Site | Houston | Texas | 77002 | — |
| Theravance Biopharma Investigational Site | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 150 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03758443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 15, 2022 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03758443 live on ClinicalTrials.gov.